Navigation Links
OncoSec Medical to Present at the 15th Annual BIO CEO & Investor Conference
Date:2/6/2013

SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon , President and CEO, will present at the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City, on Tuesday, February 12th at 3:00PM Eastern Time.

(Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)

ABOUT THE BIO CEO & INVESTOR CONFERENCE
The 15th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies.  This year's conference will feature corporate presentations from more than 150 leading biotechnology and pharmaceutical companies, five Fireside Chats with industry leaders, three Therapeutic Workshops and five Business Roundtables all drawing from seasoned industry executives and analysts. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. To find out more information on the event, visit http://www.bio.org/events/conferences/bio-ceo-investor-conference

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec Medical to Present at Noble Financial Capital Markets Ninth Annual Equity Conference on January 22
2. OncoSec Medical Announces $7.2 Million Public Offering
3. OncoSec Medical to Present Data at DNA Vaccines 2012 Conference
4. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
5. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
6. OncoSec to Present at Upcoming Healthcare and Investor Conferences
7. OncoSec Granted New Patent from China
8. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
9. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
10. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
11. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... company developing its Symphony® CGM System as a ... that Robert F. Doman , Executive Chairman ... at "TEN", Noble Financial Capital Markets, Tenth Annual ... make a corporate presentation to prospective corporate partners ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ... price of $2.92 per share, net to the seller ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc ... innovator of less invasive, miniaturized circulatory support technologies ... failure, today announced that it expects revenues for ... $53 million, bringing expected full-year 2013 revenues to ... growth of 87% for 2013 above 2012 reflects ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Perrigo Company (Nasdaq: PRGO ; TASE) today announced ... fiscal 2010 on Monday, November 2, 2009 at approximately 8:00 ... at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo,s ... be available live via webcast to interested parties on the ...
... As previously announced, WebMD Health Corp. (Nasdaq: WBMD ) ... Annual Meetings of Stockholders beginning at 9:30 a.m. Eastern Time on ... of the meetings will be available over the Internet. To listen ... www.wbmd.com (in the Investor Relations section) or at ...
Cached Medicine Technology:WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders 2
(Date:4/14/2014)... by HIV/AIDS in South Africa may provide insight on ... issues in other areas of the world, which may ... could lead to successful interventions. , A report ... Nations mentions that due to the HIV/AIDS pandemic, which ... children are at an increased risk for mental health ...
(Date:4/14/2014)... and American Associations for Dental Research (IADR/AADR) have ... Their Dental, Oral, and Craniofacial Manifestations." The complete ... Burke, Alison M. Boyce, Michael Collins, Brian L. ... Scott Ramnitz, Martha J. Somerman and J. Timothy ... the IADR/AADR Journal of Dental Research ...
(Date:4/14/2014)... IL A new study shows that moderate to ... increased risk of stroke, cancer and death. , Results ... moderate to severe obstructive sleep apnea were four times ... four times more likely to have a stroke (HR ... cancer (HR = 3.4), and 2.5 times more likely ...
(Date:4/14/2014)... 10, 2014. John DeLuca, PhD, and Yael Goverover, PhD, ... study how persons with multiple sclerosis (MS) perform everyday ... Reality to Measure Everyday Life Functional Activity in Multiple ... DeLuca is senior VP of Research & Training at ... York University, is a visiting scientist at Kessler Foundation. ...
(Date:4/14/2014)... a UT Dallas study involving serious youth offenders, the answer ... the next seven years: "How long do you think you,ll ... future encourages offending over time., Author Dr. Alex Piquero said ... life ahead of them offend at very high rates and ... to die much later in life offend much less., "In ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2
... , FERNDALE, Mich. and NEW YORK, Aug. ... today the acquisition of PRESCRIBED solutions [CUSTOMIZED SKINCARE]. Since ... among top dermatologists and plastic surgeons with its innovative, customizable ... product Stop the Clock(TM) Triple Action Anti-aging Day ...
... , SAN FRANCISCO, Aug. 14 While natural ... higher than 50 percent and none have been clinically proven to regulate ... e alth International (NHI), a vertically integrated San ... line has been clinically proven to alleviate symptoms of menopause in ...
... minimize the risk as fall looms, experts say , FRIDAY, ... year have another worry besides homework and lunchroom bullies: swine ... early and vigorously to reduce their risk of contracting the ... is going to strike the school-age child and it,s primarily ...
... , , BELLEVUE, Wash., Aug. ... solutions, today announced the new Edifecs5010(TM) Compliance ... and services for healthcare providers, payers, health plans, ISVs, and clearinghouses ... , , Edifecs, the gold standard for HIPAA ...
... , , KENILWORTH, N.J., Aug. ... announced that the U.S. Food and Drug Administration (FDA) has ... in adults and acute treatment of manic or mixed episodes ... in adults. SAPHRIS can be used as a first-line treatment ...
... , NEW YORK, Aug. 14 MS -- ... by AstraZeneca, found that while most patients with asthma understand ... accordingly. , , "This finding demonstrates ... and the necessary steps people should take to achieve better ...
Cached Medicine News:Health News:Biopelle, Inc. Acquires PRESCRIBEDsolutions [CUSTOMIZED SKINCARE](R) 2Health News:Biopelle, Inc. Acquires PRESCRIBEDsolutions [CUSTOMIZED SKINCARE](R) 3Health News:When it Comes to Natural Remedies for Hormonal Balance, the Proof is in the Clinical Research 2Health News:Get Smart About Swine Flu for Back-to-School 2Health News:Get Smart About Swine Flu for Back-to-School 3Health News:Edifecs Launches the Edifecs5010(TM) Compliance Suite of Tools, Resources and Services for 5010 Migration. 2Health News:Edifecs Launches the Edifecs5010(TM) Compliance Suite of Tools, Resources and Services for 5010 Migration. 3Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 2Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 3Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 4Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 5Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 6Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 7Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 8Health News:Keeping Asthma Under Control 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: